Abemaciclib
eli lilly
['abemaciclib', 'bcsm', 'abema']
the 4-year idfs rate for patients aged 65 years or older who received abemaciclib plus endocrine therapy was 82.0% vs 76.8% for patients who received endocrine therapy alone. #bcsm #asco23 | 
Home of the journal ONCOLOGY®, CancerNetwork® offers different perspectives on oncology/hematology through review articles, news, podcasts, blogs, and more.